<DOC>
<DOCNO>EP-0652762</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NOVEL ANXIOLYTIC
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2500	A61P2522	A61K3600	A61K3616	A61K3616	A61K3600	A61P2520	A61K369068	A61K3688	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	A61K	A61K	A61K	A61K	A61P	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61P25	A61K36	A61K36	A61K36	A61K36	A61P25	A61K36	A61K36	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A medicament containing active substances from Rhizoma zingiberis and Ginkgo bilobae is used for treating anxiety.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ARROWDEAN LTD
</APPLICANT-NAME>
<APPLICANT-NAME>
ARROWDEAN LTD.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HAECKER RUEDIGER
</INVENTOR-NAME>
<INVENTOR-NAME>
MATTERN CLAUDIA
</INVENTOR-NAME>
<INVENTOR-NAME>
HAECKER, RUEDIGER
</INVENTOR-NAME>
<INVENTOR-NAME>
MATTERN, CLAUDIA
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of a composition containing active substances
from Rhizoma zingiberis and Ginkgo bilobae for

preparing a drug for treatment of anxiety states.
Use according to claim 1, characterised in that
the composition contains a combination of extracts of

Rhizoma zingiberis and Ginkgo bilobae.
Use according to claim 2, characterised in that
the active substances or extracts in an ingestion unit

are present in capsule form or another solid or liquid
medicinal form suitable for oral application.
Use according to claim 2 or 3, characterised in
that the content of Rhizoma zingiberis extract is

between 50 and 200 mg per ingestion unit.
Use according to claim 4, characterised in that
the content of Rhizoma zingiberis extract is about 100

mg per ingestion unit.
Use according to any of claims 2 to 5,
characterised in that the content of Ginkgo bilobae

extract is between 10 and 100 mg per ingestion unit.
Use according to claim 6, characterised in that
the content of Ginkgo bilobae extract is about 40 mg

per ingestion unit.
Use according to any of claims 2 to 7,
characterised in that the Rhizoma zingiberis extract is 

obtained by ethanol/water or acetone/water extraction
and is substantially in oleoresin form.
Use according to any of claims 2 to 7,
characterised in that the Rhizoma zingiberis extract is

obtained by extraction with CO
2
.
Use according to claim 8 or 9, characterised in
that the oleoresin or CO
2
 extract of Rhizoma zingiberis
is converted into a suitable galenic form by micro-encapsulation,

granulation or freeze-drying.
</CLAIMS>
</TEXT>
</DOC>
